{"id":8395,"date":"2025-11-15T13:12:37","date_gmt":"2025-11-15T13:12:37","guid":{"rendered":"https:\/\/blog.mygenericpharmacy.com\/?p=8395"},"modified":"2025-11-15T13:17:47","modified_gmt":"2025-11-15T13:17:47","slug":"fda-approves-donanemab-to-treat-early-alzheimers-what-experts-think","status":"publish","type":"post","link":"https:\/\/blog.mygenericpharmacy.com\/index.php\/2025\/11\/15\/fda-approves-donanemab-to-treat-early-alzheimers-what-experts-think\/","title":{"rendered":"FDA approves donanemab to treat early Alzheimer&#8217;s: What experts think"},"content":{"rendered":"\n<p>The FDA&#8217;s approval of donanemab (to be marketed under the brand name&nbsp;<strong>Kisunla<\/strong>) is a landmark event in the treatment of Alzheimer&#8217;s disease. Here is a comprehensive breakdown of what the experts are saying, reflecting the consensus, the hope, and the caution.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Headline: A New Era of Treatment<\/h3>\n\n\n\n<p>The FDA has approved donanemab, a monoclonal antibody therapy, for the treatment of early symptomatic Alzheimer&#8217;s disease. This includes patients with mild cognitive impairment (MCI) or mild dementia stages of the disease, who have a confirmed presence of amyloid plaques in the brain.<\/p>\n\n\n\n<p>Donanemab joins&nbsp;<strong>lecanemab (Leqembi)<\/strong>&nbsp;as the second drug in its class to be fully approved in the U.S. that changes the underlying course of the disease by clearing amyloid.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">What the Experts Are Saying: A Spectrum of Opinions<\/h3>\n\n\n\n<p>The expert reaction is broadly positive but nuanced, characterized by &#8220;cautious optimism.&#8221; Here\u2019s a breakdown of their key points:<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">1. The Hopeful and Encouraged View: &#8220;A Turning Point&#8221;<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>It validates the Amyloid Hypothesis:<\/strong>\u00a0For decades, the theory that clearing amyloid-beta plaques could slow Alzheimer&#8217;s was just that\u2014a theory. The success of donanemab and lecanemab proves that\u00a0<strong>targeting amyloid is a viable therapeutic strategy.<\/strong>\u00a0Experts see this as a definitive turning point after many past failures.<\/li>\n\n\n\n<li><strong>Meaningful Slowing of Decline:<\/strong>\u00a0In the pivotal clinical trial, donanemab demonstrated a\u00a0<strong>significant slowing of clinical decline by about 35% over 18 months<\/strong>\u00a0compared to a placebo. For patients and families, this translates to more time to live independently, participate in family events, and manage personal finances.<\/li>\n\n\n\n<li><strong>A Dosing Endpoint:<\/strong>\u00a0A unique and patient-friendly feature of donanemab is that treatment can be stopped once a patient&#8217;s amyloid plaques are reduced to a very low level. This &#8220;treat-to-clear&#8221; protocol means patients aren&#8217;t necessarily on the drug for life, potentially reducing long-term costs and side effects.<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Expert Quote (Representative):<\/strong>&nbsp;<em>&#8220;This is the decade where we go from theory to practice. We now have tools that can meaningfully change the trajectory of this disease. It&#8217;s not a cure, but it&#8217;s the most important breakthrough we&#8217;ve ever had.&#8221;<\/em>&nbsp;\u2013 Dr. Ronald Petersen, Director of the Mayo Clinic Alzheimer&#8217;s Disease Research Center.<\/p>\n<\/blockquote>\n\n\n\n<h4 class=\"wp-block-heading\">2. The Cautious and Pragmatic View: &#8220;A Step, Not a Finish Line&#8221;<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Significant Risks and Side Effects:<\/strong>\u00a0The most serious side effects are\u00a0<strong>Amyloid-Related Imaging Abnormalities (ARIA)<\/strong>. ARIA can manifest as brain swelling (ARIA-E) or micro-bleeds (ARIA-H). While often asymptomatic and detectable only on MRI, it can be serious and, in rare cases, fatal. Expert consensus is that these risks must be carefully managed.<\/li>\n\n\n\n<li><strong>Modest Benefit for a High Cost:<\/strong>\u00a0The 35% slowing is statistically significant, but experts caution that the\u00a0<em>absolute<\/em>\u00a0benefit for an individual patient may feel modest. They weigh this against the very high cost of the drug (Eli Lilly has set a list price of\u00a0<strong>$32,000 per year<\/strong>\u00a0for donanemab, similar to Leqembi) and the extensive healthcare infrastructure required.<\/li>\n\n\n\n<li><strong>The Infrastructure Challenge:<\/strong>\u00a0Administering these drugs is not simple. It requires:\n<ul class=\"wp-block-list\">\n<li><strong>Accurate Early Diagnosis:<\/strong>\u00a0Confirming early Alzheimer&#8217;s with PET scans or cerebrospinal fluid tests.<\/li>\n\n\n\n<li><strong>Genetic Testing:<\/strong>\u00a0For ApoE \u03b54 status, as carriers have a higher risk of ARIA.<\/li>\n\n\n\n<li><strong>Specialized Infusion Centers:<\/strong>\u00a0For monthly IV treatments.<\/li>\n\n\n\n<li><strong>Frequent MRI Monitoring:<\/strong>\u00a0To check for ARIA.<br>Many healthcare systems, especially in rural or underserved areas, are not yet equipped for this.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Expert Quote (Representative):<\/strong>&nbsp;<em>&#8220;This is a qualified victory. The benefit is real but incremental, and the risks are substantial. The challenge now is to build a system that can deliver these drugs safely, equitably, and only to those who are likely to benefit.&#8221;<\/em>&nbsp;\u2013 Dr. Jason Karlawish, Co-Director of the Penn Memory Center.<\/p>\n<\/blockquote>\n\n\n\n<h4 class=\"wp-block-heading\">3. The Future-Oriented View: &#8220;A Foundation to Build Upon&#8221;<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Combination Therapies are the Future:<\/strong>\u00a0Experts see donanemab not as the end, but as a foundational treatment. The next logical step is to combine amyloid-clearing drugs with therapies that target\u00a0<strong>tau<\/strong>\u00a0(the other key Alzheimer&#8217;s protein) and drugs that protect nerve cells. Donanemab is the &#8220;first piece of the puzzle.&#8221;<\/li>\n\n\n\n<li><strong>Earlier Intervention is Key:<\/strong>\u00a0The trials show that the earlier you treat, the greater the benefit. This is fueling a massive push for\u00a0<strong>better, cheaper, and more accessible blood tests (e.g., p-tau217)<\/strong>\u00a0to identify at-risk individuals long before significant symptoms appear.<\/li>\n\n\n\n<li><strong>Prevention on the Horizon:<\/strong>\u00a0The ultimate goal is to use these drugs in the\u00a0<strong>pre-symptomatic stage<\/strong>\u00a0to prevent the disease altogether. Trials are already underway in this direction.<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Expert Quote (Representative):<\/strong>&nbsp;<em>&#8220;Donanemab is a critical proof-of-concept. It tells us we&#8217;re on the right path. Now, we need to build on this success by targeting other aspects of the disease and moving treatment earlier, ultimately aiming for prevention.&#8221;<\/em>&nbsp;\u2013 Dr. Reisa Sperling, Director of the Center for Alzheimer Research and Treatment at Brigham and Women&#8217;s Hospital.<\/p>\n<\/blockquote>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Connecting Back to the Predictive Tool<\/h3>\n\n\n\n<p>This approval makes the&nbsp;<strong>predictive tool for Alzheimer&#8217;s risk<\/strong>&nbsp;mentioned in the previous article even more relevant.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early Identification is Everything:<\/strong>\u00a0With an effective treatment now available, identifying people at high risk for memory decline\u00a0<em>before<\/em>\u00a0it becomes significant is crucial. The predictive tool (using APOE, MMSE, and subjective complaints) could be a first-line, low-cost method to flag individuals who should then undergo more definitive testing (amyloid PET or blood tests) to see if they are candidates for donanemab.<\/li>\n\n\n\n<li><strong>A Pathway to Treatment:<\/strong>\u00a0The workflow becomes:\u00a0<strong>Risk Calculator -> Confirmatory Amyloid Test -> Donanemab Treatment.<\/strong>\u00a0This creates a proactive pathway from risk assessment to intervention.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusion: A Watershed Moment with Work Ahead<\/h3>\n\n\n\n<p>The consensus among experts is clear:&nbsp;<strong>The FDA&#8217;s approval of donanemab is a watershed moment for the Alzheimer&#8217;s field.<\/strong>&nbsp;It provides a new, effective treatment option that meaningfully slows the disease.<\/p>\n\n\n\n<p>However, it comes with significant challenges regarding safety, cost, and healthcare delivery. The excitement is tempered by a sober understanding of the work required to integrate this therapy into real-world practice. For patients and families, it represents a new, tangible hope\u2014a chance to buy more quality time in the early stages of a devastating disease.<\/p>\n\n\n\n<p>Reference:<br><a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease\nhttps:\/\/www.medicalnewstoday.com\/articles\/fda-approves-alzheimers-drug-donanemab\nhttps:\/\/www.alz.org\/alzheimers-dementia\/treatments\/donanemab\nhttps:\/\/www.neurologylive.com\/view\/eli-lilly-anti-amyloid-therapy-donanemab-gains-eu-approval-alzheimer-disease\" target=\"_blank\" rel=\"noopener\" title=\"\">https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease<br>https:\/\/www.medicalnewstoday.com\/articles\/fda-approves-alzheimers-drug-donanemab<br>https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/donanemab<br>https:\/\/www.neurologylive.com\/view\/eli-lilly-anti-amyloid-therapy-donanemab-gains-eu-approval-alzheimer-disease<\/a><\/p>\n\n\n\n<p>Medications that have been suggested by doctors worldwide are available on the link below<br><a href=\"https:\/\/mygenericpharmacy.com\/category\/products\/disease\/alzheimer-disease\" target=\"_blank\" rel=\"noopener\" title=\"\">https:\/\/mygenericpharmacy.com\/category\/products\/disease\/alzheimer-disease<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA&#8217;s approval of donanemab (to be marketed under the brand name&nbsp;Kisunla) is a landmark event in the treatment of Alzheimer&#8217;s disease. Here is a comprehensive breakdown of what the experts are saying, reflecting the consensus, the hope, and the caution. The Headline: A New Era of Treatment The FDA has approved donanemab, a monoclonal antibody therapy, for the treatment of early symptomatic Alzheimer&#8217;s disease. This includes patients with mild cognitive impairment (MCI) or mild dementia stages of the disease,&#8230;<\/p>\n<p class=\"read-more\"><a class=\"btn btn-default\" href=\"https:\/\/blog.mygenericpharmacy.com\/index.php\/2025\/11\/15\/fda-approves-donanemab-to-treat-early-alzheimers-what-experts-think\/\"> Read More<span class=\"screen-reader-text\">  Read More<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[3629],"tags":[],"class_list":["post-8395","post","type-post","status-publish","format-standard","hentry","category-alzheimer"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/8395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/comments?post=8395"}],"version-history":[{"count":2,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/8395\/revisions"}],"predecessor-version":[{"id":8398,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/8395\/revisions\/8398"}],"wp:attachment":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/media?parent=8395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/categories?post=8395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/tags?post=8395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}